Skip to main content
MANE logo

MANE

Veradermics, Inc
$119.60 -5.31 (-4.25%) At close · Jul 10
Market Cap
$5.00B
Shares
41,778,687

Price & Indicators

20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$119.60 Open$124.47 Day$117.00–125.04 52W$32.00–131.24 Avg vol 30d659K Short int3.8M · 9.1% float · 3.6d Short vol64% Last earningsApr 27, 2026 DataFeb 2026–Jul 2026 Filing10-Q · May 12
Up next
FQ3-26 quarter ends
~Sep 30, 2026 Est
filed May 12, 2026
Equibles Rating blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Limited Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 15 · calm Equity put/call 0.55
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 50-day avg +13%
above
RSI (14) 57
neutral
MACD trend Positive
52-week position 88%
near high
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
2 of 80 funds reported for Jun 30 · net +74 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.12% of float · ▲ +52.9% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
80 holders — 13F breadth
Squeeze score 73
high risk · 0–100
Fundamentals
Weak
EPS growth −202%
Y/Y
Free cash flow $-71.6M
Balance sheet $21.8M
net cash
Quant / Vol
risk profile
Very High
Volatility 109%
annualized · 1-yr
Max drawdown −21%
past year
ATR 6.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
0 · 3 · 3
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
+13% Bullish
RSI (14)
57 Neutral
MACD trend
Positive Bullish
52-week position
88% Bullish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
2 of 80 funds reported for Jun 30 · net +74 sh shares · +2 new
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.12% of float · ▲ +52.9% MoM · 3.6 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
80 holders — 13F breadth
Price context
position in its 52-week range
52-wk low $32 Now $120 · 88% 52-wk high $131
vs 50-day avg +13%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
MANE
Veradermics, Inc
this stock
$5.00B 9.1%
ONC
BeOne Medicines Ltd.
$431.70B -1.7% +22179.2% 878.5 0.1%
VRTX
Vertex Pharmaceuticals Inc / Ma
$123.19B +7.1% +46.2% 28.8 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$69.67B -13.8% +20.8% 16.2 3.3%
ARGX
Argenx SE
$54.85B +4.4% 2.3%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
82
% held
62.1%
Reported
2 of 80
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
41
View
Short & Settlement
Short Interest Rising
Shares short
3.8M
Days to cover
3.6d
Change
+1.3M sh
View
Short Volume
Short vol %
64%
As of
Jul 10, 2026
Short Total
View
Fails to Deliver
FTD shares
82
Value
$7.6K
As of
Jun 11, 2026
View
Off-Exchange
Off-exchange %
56.0%
Week of
May 4, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-70.0M
EPS diluted
$-111.91
View
Filings
SEC Filings
Latest
Investor Event Transcript
Filed
Jun 30, 2026
This year
10
View
Exempt Offerings
Offering
$30.0M
Filed
May 15, 2026
View
Earnings & Events
Earnings Calls
Last call
Jun 8, 2026
View

Performance

5D 20D 120D MTD YTD
MANE -7.8% +28.6% -2.7%
SPY +1.4% +4.1% +9.1% +1.1% +10.7%
vs SPY -9.2% +24.6% -3.8%
Key facts CIK 1827635 CUSIP 922967104 13F (30d) 2 filings 2 filers Visit website Investor relations